CSE:PHRM - Post Discussion
Post by
AwareInvestor on Feb 04, 2021 8:28am
PharmaTher To Commence Phase 2 Clinical Study On Ketamine In
Pharmather is successfully progressing on the development of its proposed phase 2 clinical study on ketamine in the use of levodopa-induced dyskinesia in patients with Parkinson’s disease. The company this morning announced that it has successfully completed a Type B pre-investigational new drug meeting with US FDA.
Be the first to comment on this post